Release Details
2 November, 2015
Applied DNA Sciences, Inc. announced that it has shipped its first orders of DNA used as a diagnostic reagent to reagent suppliers and two international diagnostics customers. The total value of these shipments, which were made in its fiscal 2015 fourth quarter and the current fiscal first quarter, is over $400,000.
On September 11, 2015, APDN announced the acquisition of Vandalia Research, Inc., whose core technology and intellectual property portfolio allows for the large-scale production of specific DNA sequences using polymerase chain reaction (PCR). As part of the acquisition, Applied DNA assumed Vandalia’s backlog of orders.
Dr. James Hayward, CEO of Applied DNA Sciences, stated: “With the fulfillment of these orders, we are already beginning to reap the benefits of the acquisition. Whereas Vandalia’s PCR technology enhances our in-house DNA manufacturing capacity as demand drivers strengthen across key business verticals, it simultaneously provides us entrée into biotechnology, pharmaceutical and diagnostic markets. As we continue to provide contract production of DNA to clients in these markets, we plan to also introduce them to our DNA-based security solutions to protect their products against theft of their IP and the invasion of counterfeits into their supply chains.”
DNA production by PCR is not a broadly available commercial service, especially at large scale. The advantage of PCR-based production is the purity of product compared to the DNA produced by the more commonly available fermentation methods. DNA-based diagnostic reagents may be used in the early detection of cancer, or the diagnosis of genetic, metabolic or infectious diseases. DNA-based therapeutics may be used in gene therapies, DNA vaccines, and other therapies that are generally in the early stage of development. By providing the production of DNA for diagnostics and therapeutics, APDN expects to gain access to pharmaceutic customers who will likely have supply chain concerns, and need to protect themselves against the potential of counterfeit infiltration and comply with FDA efforts to eliminate counterfeits.
“Double-stranded DNA is fundamental to the biotechnology, pharmaceutical and diagnostics markets and we believe our capacity to manufacture it by PCR is unsurpassed in the world,” concluded Dr. Hayward. “Unlike “synthetic DNA” which is single-stranded, double-stranded DNA provides more informational content and is less subject to degradation, which can lead to an inability to authenticate when the need is critical. Much of our patent portfolio addresses the stability of our double-stranded DNA markers, which, when supplemented by Vandalia’s enhancements to our manufacturing capabilities, delivers cutting-edge value, purity of product and capacity to manufacture to the demanding specifications these markets require. With leadership positions in double-stranded DNA and its manufacture, we believe we are well positioned to succeed in these markets.”
About Applied DNA Sciences
Applied DNA Sciences makes life real and safe by providing biotechnology-driven solutions to help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Patented botanical DNA solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature DNA is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping® , targeted toward textiles and apparel, DNAnet® , for anti-theft and loss prevention, and digitalDNA® , providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators.
Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2015, May 11,2015 and August 10, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law
